|
Study Explores Pathology of Pediatric Chronic Post-op Pain
Long-term chronic postsurgical pain is common in pediatric patients, occurs across a wide range of surgeries and has a marked impact on children’s quality of life, a new survey study by SPPM member T. Anthony Anderson, MD, PhD has concluded. Dr. Anderson will be presenting a lecture at our upcoming annual meeting in Tampa, Florida. CLICK HERE to a profile on this study in Anesthesiology News.
NIH Pain Consortium Webinar: Preparing/Writing the Application/Submitting the Grant
Dear Pain Researchers,
We are reaching out to remind you about the next NIH Pain Consortium webinar in our series on NIH grant mechanisms in pain research across career stages (training, transition and independent stages).
The ninth webinar will be held on January 13, 2022, from 3:00pm-5:00 (U.S. Eastern time), and will focus on “Preparing/Writing the Application/Submitting the Grant.” This session will feature an experienced NIH-funded principal investigator sharing their insights about the grant submission process, as well as a question and answer session.
Primary Target Audience: Researchers with limited experience submitting applications to NIH
There is no cost for these webinars, but attendees must register in advance. The link to register can be found HERE. You may choose to register for any one of the sessions at this time, but we will also send out reminders as each one approaches.
The webinars will be recorded and after each one concludes it will be posted on the NIH Pain Consortium Website [https://www.painconsortium.nih.gov/meetings-events/seminars-workshops/nih-pain-consortium-grant-mechanism-webinar-series] for those who are unable to participate live and for future reference.
If you have any questions about these webinars, please feel free to contact one of the program directors listed below. We look forward to your participation.
Sincerely,
Inna Belfer, PhD
Program Director, NCCIH ([email protected])
DP Mohapatra, PhD
Program Director, NINDS ([email protected])
Laura Wandner, PhD
Program Director, NINDS ([email protected])
Upcoming Webinars and Dates
- How to Build a Budget – February 10
- Programs to Support Technology Development – March 10
Question of the Month – January 2022
For January's Question of the Month, Dr. Rita Agarwal teamed up with a parent of and advocate for children with hereditary pancreatitis and chronic or recurrent pain, Beth Larson-Steckler https://www.childhoodpancreatitis.org/
This question is based on composite patient experience and is not meant as a critique of healthcare professionals in pediatric pain management, but a reflection of lived experience of patients and their families. Many families with children with chronic pain live in areas with limited access to health care and attempting to get appropriate care for their children can be challenging. These families often rely on their PCP and have minimal access to specialists.
Question: My 13-year-old daughter has acute and chronic pain related to hereditary pancreatitis that was well controlled on a stable dose of opioids. Her pediatrician switched her medications to gabapentin because he was concerned about the risk of opioids. Since she started taking gabapentin, she is short with us, crabby and depressed. She is crying all the time and her pain is worse. I am very concerned, I‘d like to have her switched back but her doctor keeps saying it’s better than opioids. What should I do first?
Correct!
Wrong!
Question of the Month - January 2022
CORRECT ANSWER: B. Ask your physician for a referral to a pediatric chronic pain program to explore multidisciplinary based approach to management.
Gabapentin is a medication that is commonly used for the treatment of chronic and acute pain. It’s exact mechanism of action in relieving pain is not known, although gabapentin and pregabalin are hypothesized to work via modulation of voltage-gated calcium channels1. It may be effective in some patients and is often used for neuropathic pain but may take up to 4 weeks for effect. It has some side effects, including mood dysregulation, sedation, and irritability that require close monitoring when initially prescribed. 2,3. If a child is not getting relief from gabapentin or having side effects that are difficult to manage, parents should be encouraged to talk to their physician about changing medications or adjusting the dose. There are other medications that may work better with less side effects. However, many parents navigating these changes often worry that they or their child will get labeled as difficult, doctor shopping, or drug seeking. This is particularly true for families that live in rural areas or locations with limited access to specialist healthcare. In a survey by the US Pain Foundation less than 50% of patients are cared for by a pain specialist and almost 40% of families have tried unsuccessfully to see a pain specialist.4
The use of long-term opioids in patients with chronic pain is controversial.5,6,7,8 Previously patients including children with chronic non-cancer pain were sometimes prescribed opioids and were getting relief from stable doses of opioids. However, with the increasing evidence regarding the lack of long-term efficacy, and potential harm from opioid use and with the 2016 CDC Guideline regarding prescribing opioids for chronic pain many practitioners are choosing to, or being forced by institutional policies to summarily stop prescribing opioids, in some cases without adequate appropriate alternative multimodal therapy. Families should first discuss these options with their health professional. Multimodal and multidisciplinary techniques to pain management in children have been shown to be the most effective approach.
If a patient’s pain is chronic and complex in nature, the family should ask for a referral to a multidisciplinary pediatric chronic pain program. Since many programs are offering telehealth visits this may be more possible or practical now for families with children living in remote areas. Most specialists in pediatric pain will manage patients with a multidisciplinary approach that includes pain psychology, physical therapy, occupational therapy, and may include psychiatry, and/or interventional procedures such as trials of nerve blocks. While in-person visits are still ideal, a lot of care including PT/OT/complementary therapy, biofeedback, mindfulness, relaxation therapy and hypnosis can be offered in a virtual setting.
Pediatric Chronic pain specialists and clinics can be found here https://pedspainmedicine.org/patients-and-families-useful-links/ or http://childpain.org/wp-content/uploads/2020/03/PedPainClinicList_2020-v2.pdf
References:
1. Mathew, E., Kim, E. & Goldschneider, K. R. Pharmacological Treatment of Chronic Non-Cancer Pain in Pediatric Patients. Pediatric Drugs 16, 457–471 (2014).
2. Li G, Li P. (2020, Summer) The use of membrane stabilizers in acute and chronic pain. SPPM Newsletter. Retrieved from https://pedspainmedicine.org/wp- content/uploads/newsletters/2020/summer/nonopioid/Membrane%20Stabilizers%20.html
3. Trends in Gabapentin and Pregabalin Prescribing in a Tertiary Pediatric Medical Center. Donado C, Nedeljkovic K, Wangnamthip S, Solodiuk JC, Bourgeois FT, Berde CB.Hosp Pediatr. 2021 Aug;11(8):909-914. doi: 10.1542/hpeds.2020-003582. Epub 2021 Jul 13.PMID: 34257145
4. US Pain Foundation. 2021 Pediatric Pain Survey, US Pain Foundation, 2021, https://uspainfoundation.org/wp-content/uploads/2021/06/2021-Pediatric-Pain-Survey-SMALL.pdf.
5. Dowell D, Haegerich TM, Chou R. CDC guideline for prescribing opioids for chronic pain—United States, 2016 JAMA. doi:10.1001/jama.2016.1464.
6. The Potential Impact on Children of the CDC Guideline for Prescribing Opioids for Chronic Pain: Above All, Do No Harm. Schechter NL, et al. JAMA Pediatr. 2016. PMID: 26977702
7. European* clinical practice recommendations on opioids for chronic noncancer pain - Part 1: Role of opioids in the management of chronic noncancer pain. Häuser W, Morlion B, Vowles KE, Bannister K, Buchser E, Casale R, Chenot JF, Chumbley G, Drewes AM, Dom G, Jutila L, O'Brien T, Pogatzki-Zahn E, Rakusa M, Suarez-Serrano C, Tölle T, Krčevski Škvarč N. Eur J Pain. 2021 May;25(5):949-968. doi: 10.1002/ejp.1736. Epub 2021 Mar 2.PMID: 33655607
8. Guidelines on the management of chronic pain in children. Geneva: World Health Organization; 2020. Licence: CC BY-NC-SA 3.0 IGO.
Gabapentin is a medication that is commonly used for the treatment of chronic and acute pain. It’s exact mechanism of action in relieving pain is not known, although gabapentin and pregabalin are hypothesized to work via modulation of voltage-gated calcium channels1. It may be effective in some patients and is often used for neuropathic pain but may take up to 4 weeks for effect. It has some side effects, including mood dysregulation, sedation, and irritability that require close monitoring when initially prescribed. 2,3. If a child is not getting relief from gabapentin or having side effects that are difficult to manage, parents should be encouraged to talk to their physician about changing medications or adjusting the dose. There are other medications that may work better with less side effects. However, many parents navigating these changes often worry that they or their child will get labeled as difficult, doctor shopping, or drug seeking. This is particularly true for families that live in rural areas or locations with limited access to specialist healthcare. In a survey by the US Pain Foundation less than 50% of patients are cared for by a pain specialist and almost 40% of families have tried unsuccessfully to see a pain specialist.4
The use of long-term opioids in patients with chronic pain is controversial.5,6,7,8 Previously patients including children with chronic non-cancer pain were sometimes prescribed opioids and were getting relief from stable doses of opioids. However, with the increasing evidence regarding the lack of long-term efficacy, and potential harm from opioid use and with the 2016 CDC Guideline regarding prescribing opioids for chronic pain many practitioners are choosing to, or being forced by institutional policies to summarily stop prescribing opioids, in some cases without adequate appropriate alternative multimodal therapy. Families should first discuss these options with their health professional. Multimodal and multidisciplinary techniques to pain management in children have been shown to be the most effective approach.
If a patient’s pain is chronic and complex in nature, the family should ask for a referral to a multidisciplinary pediatric chronic pain program. Since many programs are offering telehealth visits this may be more possible or practical now for families with children living in remote areas. Most specialists in pediatric pain will manage patients with a multidisciplinary approach that includes pain psychology, physical therapy, occupational therapy, and may include psychiatry, and/or interventional procedures such as trials of nerve blocks. While in-person visits are still ideal, a lot of care including PT/OT/complementary therapy, biofeedback, mindfulness, relaxation therapy and hypnosis can be offered in a virtual setting.
Pediatric Chronic pain specialists and clinics can be found here https://pedspainmedicine.org/patients-and-families-useful-links/ or http://childpain.org/wp-content/uploads/2020/03/PedPainClinicList_2020-v2.pdf
References:
1. Mathew, E., Kim, E. & Goldschneider, K. R. Pharmacological Treatment of Chronic Non-Cancer Pain in Pediatric Patients. Pediatric Drugs 16, 457–471 (2014).
2. Li G, Li P. (2020, Summer) The use of membrane stabilizers in acute and chronic pain. SPPM Newsletter. Retrieved from https://pedspainmedicine.org/wp- content/uploads/newsletters/2020/summer/nonopioid/Membrane%20Stabilizers%20.html
3. Trends in Gabapentin and Pregabalin Prescribing in a Tertiary Pediatric Medical Center. Donado C, Nedeljkovic K, Wangnamthip S, Solodiuk JC, Bourgeois FT, Berde CB.Hosp Pediatr. 2021 Aug;11(8):909-914. doi: 10.1542/hpeds.2020-003582. Epub 2021 Jul 13.PMID: 34257145
4. US Pain Foundation. 2021 Pediatric Pain Survey, US Pain Foundation, 2021, https://uspainfoundation.org/wp-content/uploads/2021/06/2021-Pediatric-Pain-Survey-SMALL.pdf.
5. Dowell D, Haegerich TM, Chou R. CDC guideline for prescribing opioids for chronic pain—United States, 2016 JAMA. doi:10.1001/jama.2016.1464.
6. The Potential Impact on Children of the CDC Guideline for Prescribing Opioids for Chronic Pain: Above All, Do No Harm. Schechter NL, et al. JAMA Pediatr. 2016. PMID: 26977702
7. European* clinical practice recommendations on opioids for chronic noncancer pain - Part 1: Role of opioids in the management of chronic noncancer pain. Häuser W, Morlion B, Vowles KE, Bannister K, Buchser E, Casale R, Chenot JF, Chumbley G, Drewes AM, Dom G, Jutila L, O'Brien T, Pogatzki-Zahn E, Rakusa M, Suarez-Serrano C, Tölle T, Krčevski Škvarč N. Eur J Pain. 2021 May;25(5):949-968. doi: 10.1002/ejp.1736. Epub 2021 Mar 2.PMID: 33655607
8. Guidelines on the management of chronic pain in children. Geneva: World Health Organization; 2020. Licence: CC BY-NC-SA 3.0 IGO.
NIH HEAL FOA: Developing Quantitative Imaging & Other Relevant Biomarkers of Myofascial Tissues for Clinical Pain Management
The National Institutes of Health (NIH) will sponsor two events on December 2, 2021 and January 6, 2022 related to the funding opportunity announcement (FOA) RFA-AT-22-003 HEAL Initiative: Developing Quantitative Imaging and Other Relevant Biomarkers of Myofascial Tissues for Clinical Pain Management (R61/R33, Clinical Trial Required). The FOA is a partnership between the National Center for Complementary and Integrative Health (NCCIH), the National Institute of Biomedical Imaging and Bioengineering (NIBIB), and seven other NIH Institutes, Centers, and Offices.*
Information about both events is below.
Both webinars are optional and not required for application submission. The first webinar will be recorded and archived for later viewing. The second webinar will NOT be recorded.
HEAL Initiative: Developing Quantitative Imaging and Other Relevant Biomarkers of Myofascial Tissues for Clinical Pain Management Informational Webinar
December 2, 2021, from 3 to 4 p.m. ET
This technical assistance webinar will present an overview of the initiative (RFA-AT-22-003), provide guidance on the application preparation process, and address applicant questions. All webinar registrants will be prompted to indicate their areas of expertise, what additional areas of expertise they are looking for on their teams, and whether they are willing to share their email addresses along with their areas of expertise with other webinar registrants. We are asking for this information during the Eventbrite registration to better facilitate potential team-building interactions during the second technical assistance webinar.
Please register for the informational webinar
Researchers Networking Session: Interactive Facilitated Conversations With HEAL Program Officers and Other Experts
January 6, 2022, from 3 to 4 p.m. ET
This networking session will facilitate interactive conversations with NIH program officers and other experts on topic-specific research areas for RFA-AT-22-003. This event will provide an interactive team-building experience for webinar registrants related to technical requirements of the R33 phase of the FOA. Participants will join breakout rooms.
Please register for the networking session
How to Participate
1. You must register for the webinars through Eventbrite.
2. There will be a question-and-answer portion at the end of the first webinar.
3. Registrants are encouraged to submit questions in advance.
—Registrants who indicate their needs for additional areas of expertise will be sent a list of names/emails of experts who are willing to share their contact information and are interested in collaboration.
*The NIH components participating in RFA-AT-22-003 are:
- National Center for Complementary and Integrative Health
- National Institute on Aging
- National Institute of Arthritis and Musculoskeletal and Skin Diseases
- National Institute of Biomedical Imaging and Bioengineering
- Eunice Kennedy Shriver National Institute of Child Health and Human Development
- National Institute of Dental and Craniofacial Research
- National Institute of Neurological Disorders and Stroke
- National Center for Advancing Translational Sciences
- Office of Research on Women’s Health
- « Previous Page
- 1
- …
- 29
- 30
- 31
- 32
- 33
- …
- 44
- Next Page »
SPPM 12th Annual Meeting